Penumbra(PEN)
Focus: Penumbra is a publicly-traded medical device company focused on minimally invasive vascular and surgical devices for acute care interventions, primarily in stroke and thromboembolism. They operate at scale with $1.1B in FY2025 revenue and a market-leading position in mechanical thrombectomy.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
67+12 this month
Growing — net +12 jobs in 30d
49 jobs added vs 37 removed. Steady team buildout.
Should You Work at Penumbra?
AI assessmentIdeal for commercial, operations, and quality roles in a growth-stage medical device company with strong cash generation; less suitable for scientists seeking deep R&D pipelines.
Why Work Here
- Strong revenue growth: +30% YoY ($847M to $1.1B) with return to profitability ($91M net income in FY2025) signals operational momentum and job security.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1.1B
Key Products
Penumbra System
Growing
Growth
Flagship platform with multiple indications (stroke, ischemic stroke, general stroke) across 5+ pipeline programs; core revenue driver.
Help build intelligence for Penumbra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.